Page 22 - Pharma Companies

Electronics to urea: China is everywhere in India's consumer industries

Import of mobile phone components during April-February FY20, according to government figures, hit $7.5 billion - of which 25 per cent was from the land of the dragon.

With little access to doctors, drug firms go digital to stay relevant

The rise of e-pharmacies and tele-consultations during Covid-19 has made it easier for healthcare companies to access patient pools

Panacea forms JV with Refana to develop, manufacture Covid-19 vaccine

The firm is set to make 500 million doses of the vaccine, which will then be supplied to the JV (based in the Republic of Ireland).

Covid-19 crisis: Drug sales in May down 9%, fiscal growth to be flat

Market research firm AIOCD AWACS has predicted zero growth in the domestic market this financial year.

Global law firms discuss lockdown compensation suits, India too at risk

Lawyers agree that at present the probability of such a suit arising is very low, but not unlikely

AstraZeneca, Gilead merger likely to hit political, strategic hurdles

Political opposition from both the UK and the US could derail any attempt at a deal, especially given the backdrop of the Covid-19 outbreak, Citigroup said

Blueprint for a more healthy economy

What we need is a map - an economic blueprint - that will address the need for domestic growth and put in place measures that will make India attractive for foreign investment.

Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.

Is India right in recommending HCQ despite the uncertainties around it?

HCQ was dropped from the solidarity trial that WHO was conducting as a part of a global effort in May.

Russia backing antiviral drug Avifavir for Covid fight good news for India

Avifavir, described by its developers in Russia as perhaps the most promising anti-Covid-19 drug in the world, is derived from Favipiravir.

Gilead Sciences developing easy-to-administer version of remdesivir

Remdesivir is the only drug so far that has been shown to help patients with Covid-19, but Gilead and other companies are looking for ways to make it work better.

Covid-19 crisis: Indian drug companies yet to get nod to market remdesivir

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

Pharma companies refine SOPs after Covid-19 cases, deaths in Gujarat

Apart from the general sanitization of buses and plants, Lupin and many other pharma companies have now started sanitising raw material entering the plant

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Covid-19 crisis prompts India to look for global partners in health care

Medical devices industry has potential to attract Rs 70,000 crore in 5 years

First copies of Gilead coronavirus drug to start selling in Bangladesh

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

AstraZeneca says data from Covid-19 vaccine's phase-1 trials to be out soon

Once the late stage trials begin, the company simultaneously will start working on the global manufacturing capabilities.

GlaxoSmithKline Q4 consolidated net profit declines 6% to Rs 138 cr

The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries

PM Modi announces Rs 20 trillion stimulus package to jump-start economy

'Self-reliant India' package is around 10% of GDP; lockdown 4.0 is on with new guidelines